Completed PHASE3 INTERVENTIONAL 2-arm NCT03126435

EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX

A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1+GEM vs GEM Alone in Patients With Measurable Locally Advanced/Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment

Sponsor: SynCore Biotechnology Co., Ltd.

Conditions Locally Advanced Pancreatic Cancer Metastatic Pancreas Cancer Pancreatic Adenocarcinoma

Interventions EndoTAG-1 Gemcitabine

Updated 20 times since 2017 Last updated: May 5, 2023 Started: Oct 16, 2018 Primary completion: Jul 30, 2021 Completion: Oct 8, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Locally Advanced Pancreatic Cancer and Metastatic Pancreas Cancer and is currently completed. SynCore Biotechnology Co., Ltd. leads this study, which shows 20 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

20 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Dec 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2023 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 15 earlier versions

Apr 2023 — Jun 2023 [monthly]

Completed PHASE3
May 2022 — Apr 2023 [monthly]

Completed PHASE3
Feb 2022 — May 2022 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Oct 2021 — Feb 2022 [monthly]

Active Not Recruiting PHASE3
May 2021 — Oct 2021 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2021 — May 2021 [monthly]

Recruiting PHASE3
May 2020 — Jan 2021 [monthly]

Recruiting PHASE3
Jun 2019 — May 2020 [monthly]

Recruiting PHASE3
May 2019 — Jun 2019 [monthly]

Recruiting PHASE3
Nov 2018 — May 2019 [monthly]

Recruiting PHASE3
Oct 2018 — Nov 2018 [monthly]

Recruiting PHASE3
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE3
Aug 2018 — Sep 2018 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jun 2018 — Aug 2018 [monthly]

Not Yet Recruiting PHASE3
Jun 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

SynCore Biotechnology Co., Ltd.

Data source: SynCore Biotechnology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Arkhangelsk, Russia , Atlanta, United States , Besançon, France , Bordeaux, France , Brest, France , Budapest, Hungary , Changhua, Taiwan , Charlottesville, United States , Cholet, France and 48 more locations